We report the clinical and dopamine transporter/D2 receptor single-photon emission computed tomographic (SPECT) imaging findings in a 39-year-old woman with a 24-year history of dopa-responsive dystonia (DRD). The SPECT imaging of the dopamine transporter with [99mTc]TRODAT-1 is helpful in differentiating DRD from early-onset idiopathic parkinsonism. In the later clinical course, the [123I]IBZM SPECT is also helpful in differentiating these two conditions. The patient showed a dramatic and sustained response to levodopa, and needed a smaller dose of levodopa for symptom control in the later course.

Keywords:
Dopa-responsive dystonia, Early-onset idiopathic parkinsonism, [99mTc]TRODAT-1 SPECT, [123I]IBZM SPECT
1.
Hwang WJ, Calne DB, Tsui JKC, de la Fuente-Fernández R: The long-term response to levodopa in dopa-responsive dystonia. Parkinsonism Relat Disord 2001;8:1–5.
2.
Rajput AH, Gibb WR, Zhong XH, Shannak KS, Kish S, Chang LG, Hornykiewicz O: Dopa-responsive dystonia: Pathological and biochemical observations in a case. Ann Neurol 1994;35:396–402.
3.
Jeon BS, Jeong JM, Park SS, Kim JM, Chang YS, Song HC, Kim KM, Yoon KY, Lee MC, Lee SB: Dopamine transporter density measured by [123I]β-CIT single-photon emission computed tomography is normal in dopa-responsive dystonia. Ann Neurol 1998;43:792–800.
4.
Naumann M, Pirker W, Reiners K, Lange K, Becker G, Brücke T: [123I]β-CIT single-photon emission tomography in dopa-responsive dystonia. Mov Disord 1997;12:448–451.
5.
O’Sullivan JD, Costa DC, Gacinovic S, Lees AJ: SPECT imaging of the dopamine transporter in juvenile-onset dystonia. Neurology 2001;56:266–267.
6.
Huang CC, Yen TC, Weng YH, Lu CS: Normal dopamine transporter binding in dopa responsive dystonia. J Neurol 2002;249:1016–1020.
7.
Snow BJ, Nygaard TG, Takahashi H, Calne DB: Positron emission tomographic studies of dopa-responsive dystonia and early-onset idiopathic parkinsonism. Ann Neurol 1993;34:733–738.
8.
Sawle GV, Leenders KL, Brooks DJ, Harwood G, Lees AJ, Frackowiak RSJ, Marsden CD: Dopa-responsive dystonia: [18F]dopa positron emission tomography. Ann Neurol 1991;30:24–30.
9.
Turjanski N, Bhatia K, Burn DJ, Sawle GV, Marsden CD, Brooks DJ: Comparison of striatal 18F-dopa uptake in adult-onset dystonia-parkinsonism, Parkinson’s disease, and dopa-responsive dystonia. Neurology 1993;43:1563–1568.
10.
Künig G, Leenders KL, Antonini A, Vontobel P, Weindl A, Meinck HM: D2 receptor binding in dopa-responsive dystonia. Ann Neurol 1998;44:758–762.
11.
Kishore A, Nygaard TG, de la Fuente-Fernández R, Naini AB, Schulzer M, Mak E, Ruth TJ, Calne DB, Snow BJ, Stoessl AJ: Striatal D2 receptors in symptomatic and asymptomatic carriers of dopa-responsive dystonia measured with [11C]-raclopride and positron-emission tomography. Neurology 1998;50:1028–1032.
12.
Antonini A, Schwarz J, Oertel WH, Pogarell O, Leenders KL: Long-term changes of striatal dopamine D2 receptors in patients with Parkinson’s disease: A study with positron emission tomography and [11C]raclopride. Mov Disord 1997;12:33–38.
13.
Laulumaa V, Kuikka JT, Soininen H, Bergstrom K, Lansimies E, Riekkinen P: Imaging of D2 dopamine receptors of patients with Parkinson’s disease using single photon emission computed tomography and iodobenzamide 123I. Arch Neurol 1993;50:509–512.
14.
Pizzolato G, Chierichetti F, Rossato A, Briani C, Dam M, Borsato N, Saitta B, Zanco P, Ferlin G, Battistin L: Dopamine receptor SPET imaging in Parkinson’s disease: A [123I]-IBZM and [99mTc]-HM-PAO study. Eur Neurol 1993;33:143–148.
15.
Brooks DJ, Ibanez V, Sawle GV, Playford ED, Quinn N, Mathias CJ, Lees AJ, Marsden CD, Bannister R, Frackowiak RSJ: Striatal D2 receptor status in patients with Parkinson’s disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography. Ann Neurol 1992;31:184–192.
16.
Hwang WJ, Yao WJ, Wey SP, Shen LH, Ting G: Downregulation of striatal dopamine D2 receptors in advanced Parkinson’s disease contributes to the development of motor fluctuation. Eur Neurol 2002;47:113–117.
17.
Segawa M: Development of the nigrostriatal dopamine neuron and the pathways in the basal ganglia. Brain Dev 2000;22:S1–S4.
18.
Mozley PD, Acton PD, Barraclough ED, Plossl K, Gur RC, Alavi A, Mathur A, Saffer J, Kung HF: Effects of age on dopamine transporters in healthy humans. J Nucl Med 1999;40:1812–1817.
19.
Nygaard TG, Marsden CD, Fahn S: Dopa-responsive dystonia: Long-term treatment response and prognosis. Neurology 1991;41;174–181.
20.
de la Fuente-Fernández R: Drug-induced motor complications in dopa-responsive dystonia: Implications for the pathogenesis of dyskinesias and motor fluctuations. Clin Neuropharmacol 1999;22:216–219.
21.
Nutt JG, Holford NHG: The response to levodopa in Parkinson’s disease: Imposing pharmacological law and order. Ann Neurol 1996;39:561–573.
22.
Deuschl G, Bain P, Brin M: Consensus statement of the movement disorder society on tremor. Ad Hoc Scientific Committee. Mov Disord 1998;13(suppl 3):2–23.
23.
Furukawa Y, Mizuno Y, Narabayashi H: Early-onset parkinsonism with dystonia: Clinical and biochemical differences from hereditary progressive dystonia or dopa-responsive dystonia. Adv Neurol 1996;69:327–337.
24.
Furukawa Y, Kish SJ: Dopa-responsive dystonia: Recent advances and remaining issues to be addressed. Mov Disord 1999;14:709–715.
© 2004 S. Karger AG, Basel
2004
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.